MA43100A - Nanoparticules à utiliser en tant que vaccin thérapeutique - Google Patents

Nanoparticules à utiliser en tant que vaccin thérapeutique

Info

Publication number
MA43100A
MA43100A MA043100A MA43100A MA43100A MA 43100 A MA43100 A MA 43100A MA 043100 A MA043100 A MA 043100A MA 43100 A MA43100 A MA 43100A MA 43100 A MA43100 A MA 43100A
Authority
MA
Morocco
Prior art keywords
nanoparticles
therapeutic vaccine
vaccine
therapeutic
Prior art date
Application number
MA043100A
Other languages
English (en)
Inventor
Laurent Levy
Julie Marill
Agnès Pottier
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MA43100A publication Critical patent/MA43100A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA043100A 2015-05-28 2016-05-27 Nanoparticules à utiliser en tant que vaccin thérapeutique MA43100A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15305810 2015-05-28

Publications (1)

Publication Number Publication Date
MA43100A true MA43100A (fr) 2018-09-05

Family

ID=53298299

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043100A MA43100A (fr) 2015-05-28 2016-05-27 Nanoparticules à utiliser en tant que vaccin thérapeutique

Country Status (18)

Country Link
US (2) US11096962B2 (fr)
EP (1) EP3302419A1 (fr)
JP (2) JP2018516256A (fr)
KR (1) KR20180012823A (fr)
CN (2) CN107708668A (fr)
AR (1) AR104806A1 (fr)
AU (2) AU2016269146B2 (fr)
BR (1) BR112017025553A2 (fr)
CA (1) CA2987331A1 (fr)
EA (1) EA201792560A1 (fr)
HK (1) HK1246160A1 (fr)
IL (1) IL255853B (fr)
MA (1) MA43100A (fr)
MX (2) MX2017015424A (fr)
NZ (1) NZ738527A (fr)
TW (1) TW201705977A (fr)
UA (1) UA124572C2 (fr)
WO (1) WO2016189125A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424533A1 (fr) * 2017-07-05 2019-01-09 Nh Theraguix Procédés de traitement de la dépendance
CN109010828B (zh) * 2018-10-12 2020-10-20 中国科学院高能物理研究所 一种二硫化钼/二氧化铪的复合纳米材料、其制备方法及用途
US20210387020A1 (en) * 2018-10-19 2021-12-16 University Of Rochester Immune modulators in combination with radiation treatment for advanced pancreatic cancer
CN116507366A (zh) 2020-11-05 2023-07-28 纳米生物技术公司 用于治疗癌症的纳米颗粒组合物
WO2024126383A1 (fr) 2022-12-12 2024-06-20 Nanobiotix (Nanobiotix S.A.) Nouvelles nanoparticules d'oxyde métallique et compositions de celles-ci destinées à être utilisées en tant que radioactivateurs ou pour visualiser un tissu biologique

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US4672040A (en) 1983-05-12 1987-06-09 Advanced Magnetics, Inc. Magnetic particles for use in separations
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US6099457A (en) 1990-08-13 2000-08-08 Endotech, Inc. Endocurietherapy
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
JPH08500700A (ja) 1992-06-08 1996-01-23 バイオクエスト インコーポレイテッド 分離、磁気分子スイッチ、および医療用途の無機リポソームとして使用する粒径を制御した無機粒子の製造
EP0654973A4 (fr) 1992-07-21 1995-08-09 Gen Hospital Corp Systeme d'administration d'un medicament aux tissus lyphatiques.
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
DE69529054T2 (de) 1994-02-28 2003-08-21 Nanopharm Ag System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
JP3902794B2 (ja) 1997-03-07 2007-04-11 マックス−デルブルック−セントラム フュア モレクラーレ メディシン 特異的磁気体、その製造方法及び使用
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19726282A1 (de) 1997-06-20 1998-12-24 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern
US6161034A (en) 1999-02-02 2000-12-12 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
WO2000006244A2 (fr) 1998-07-30 2000-02-10 Hainfeld James F Particules metalliques de chargement dans des vesicules membranaires cellulaires et particule metallique utilisee pour l'imagerie et la therapie
AU4305101A (en) 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
CA2399293C (fr) 2000-02-08 2012-01-03 Rice University Nanoparticules optiquement actives destinees a etre utilisees dans des procedes therapeutiques et de diagnostic
JP2003532898A (ja) 2000-05-05 2003-11-05 バイエル アクチェンゲゼルシャフト 生体標識としてのドープ処理されたナノ粒子
ATE536550T1 (de) 2000-10-06 2011-12-15 Life Technologies Corp Halbleiter nanokristalle enthaltende transfektibare mizellen
EP1335737A2 (fr) 2000-11-20 2003-08-20 Oncolytics Biotech, Inc. Procede d'apport optimal d'un virus a une masse de tumeur solide
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
US6756063B2 (en) 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
DE10154016B4 (de) 2001-10-26 2004-02-12 Berlin Heart Ag Magnetflüssigkeit und Verfahren zur ihrer Herstellung
WO2003075961A2 (fr) 2002-03-08 2003-09-18 James Hainfeld Supports et procedes d'amelioration d'imagerie medicale
US20030191458A1 (en) 2002-04-03 2003-10-09 Cornelius Diamond Light-activated drug delivery method and device
US7769423B2 (en) 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
US20030125283A1 (en) 2002-09-16 2003-07-03 Gatenby Robert A. Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targetting agents
EP1675570B1 (fr) 2003-01-24 2016-12-14 The Research Foundation Of State University Of New York Nanoparticules à base de céramique pour encapsulation d'agents thérapeuthiques pour thérapie photodynamique et méthode d'utilisation
US7235228B2 (en) 2003-04-15 2007-06-26 The United States Of America As Represented By The Secretary Of The Navy Fluorescent-magnetic nanoparticles with core-shell structure
US20050084869A1 (en) 2003-10-20 2005-04-21 Sung Hyun Kim Novel composition and methods for the diagnosis of lung cancer
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
JP2007511503A (ja) 2003-11-17 2007-05-10 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 医療画像化技術用の造影剤及びその使用
US9750821B2 (en) 2003-12-22 2017-09-05 Bracco Suisse S.A. Gas-filled microvesicle assembly for contrast imaging
EP1720521A4 (fr) 2004-02-10 2008-11-05 Barnes Jewish Hospital Efficacite et securite ameliorees d'agents particulaires diriges a l'aide de systemes leurres
JP4895151B2 (ja) 2004-02-27 2012-03-14 日立金属株式会社 鉄系ナノサイズ粒子およびその製造方法
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20050260137A1 (en) 2004-05-18 2005-11-24 General Electric Company Contrast agents for magnetic resonance imaging
US20070031337A1 (en) 2004-06-22 2007-02-08 Reinhard Schulte Nanoparticle enhanced proton computed tomography and proton therapy
GB2415374A (en) 2004-06-25 2005-12-28 Leuven K U Res & Dev Targeted delivery of biologically active substances using iron oxide/gold core-shell nanoparticles
WO2006037081A2 (fr) 2004-09-28 2006-04-06 The Regents Of The University Of California Radiosensibiliseurs a base de nanoparticules
FR2877571B1 (fr) 2004-11-05 2007-04-13 Nanobiotix Sarl Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
EP1810688A1 (fr) 2004-11-10 2007-07-25 Konica Minolta Medical & Graphic, Inc. Préparation pharmaceutique contenant des particules magnétiques revêtues et procédé de fabrication idoine, et système de thérapie de diagnostic
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
FR2884149B1 (fr) 2005-04-12 2007-06-08 Henri Mehier Tube implantable destine a l'injection notamment de fluide caloporteur dans tout ou partie d'un tissu humain ou animal
US20070092927A1 (en) 2005-06-13 2007-04-26 University Of Dayton Photocatalytic particles with directed and controlled redox activity
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
JP2009513696A (ja) 2005-11-01 2009-04-02 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム 内部局所放射線治療用生物分解可能な複合体
US20070098642A1 (en) 2005-11-02 2007-05-03 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography
KR100745744B1 (ko) 2005-11-11 2007-08-02 삼성전기주식회사 나노 입자 코팅 방법
WO2007122956A1 (fr) 2006-03-24 2007-11-01 Toto Ltd. Particules complexes d'oxyde de titane, dispersion des particules et procédé pour la production des particules
JP2009536151A (ja) 2006-03-30 2009-10-08 富士フイルム株式会社 ナノ粒子
EP1852107A1 (fr) 2006-04-19 2007-11-07 Nanobiotix Compositions contenant des nanoparticules magnétiques et leur utilisation
AU2007247770B2 (en) 2006-05-04 2013-07-18 Reformpharm Pty Ltd Drug release from nanoparticle-coated capsules
BRPI0713940A2 (pt) 2006-07-10 2012-12-04 Konink Philips Eletronics N V nanopartìcula de núcleo e casca, e , uso e processo para fabricação da mesma
DE102006041495A1 (de) 2006-08-29 2008-03-20 Friedrich-Schiller-Universität Jena Substanzgemisch zur lokalen Deposition von Magnetpartikeln in einem Medium, insbesondere in tumorbefallenem organischem Gewebe, sowie Applikationskit zur Verabreichung
NO329127B1 (no) 2006-09-12 2010-08-30 Epitarget As Sporbart partikulaert materiale for legemiddelavlevering omfattende et matriseeller membranmateriale, et legemiddel, og et T1- og et T2*- magnetisk resonanskontrastmiddel
NO20064315L (no) 2006-09-22 2008-03-24 Epitarget As T1 MRI-sporbare medikamentavleveringspartikler and anvendelse derav
IL181126A0 (en) 2006-11-01 2007-07-04 S B Biotechnologies Ltd Preparation of gold-containing nano-liposome particles and their use in medical therapy
EP1920784A1 (fr) 2006-11-13 2008-05-14 Koninklijke Philips Electronics N.V. Sensibilisateurs de radiation pour la thérapie par rayonnements ionisants et pour l'imagerie
US20090004258A1 (en) 2007-06-27 2009-01-01 National Health Research Institutes Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field
AU2008288917A1 (en) 2007-08-21 2009-02-26 Alza Corporation Liposome compositions for in vivo administration of boronic acid compounds
JP2009067613A (ja) 2007-09-11 2009-04-02 Fujifilm Corp コア−シェル型金属酸化物微粒子及びその製造方法
US20120176016A1 (en) 2007-09-28 2012-07-12 General Electric Company Core-shell particulates, articles, and method of making
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
EP2067485A1 (fr) 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Transporteur de médicament fournissant un contraste amélioré pour l'IRM
WO2009081287A2 (fr) 2007-12-21 2009-07-02 University Of Guelph Nanoparticules de polysaccharide
DE102008003615A1 (de) 2008-01-09 2009-07-16 Magforce Nanotechnologies Ag Magnetische Transducer
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
US9403789B2 (en) 2008-02-21 2016-08-02 Sequoia Pharmaceuticals, Inc. Benzofuran-containing amino acid inhibitors of cytochrome P450
DE102008000852A1 (de) 2008-03-27 2009-10-01 Bosch Mahle Turbo Systems Gmbh & Co. Kg Abgasturbolader für ein Kraftfahrzeug
WO2009142754A1 (fr) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Conjugués dendritiques et procédés associés
EP2130553A1 (fr) 2008-06-05 2009-12-09 Nanobiotix Nanoparticules inorganiques de haute densité pour détruire des cellules in-vivo
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
US8395131B2 (en) 2009-06-20 2013-03-12 Xiaodong Wu Method for three dimensional (3D) lattice radiotherapy
EP2275137A1 (fr) 2009-07-10 2011-01-19 Nanobiotix Nanoparticules métalliques, leur préparation et utilisations
EP2305310A1 (fr) 2009-09-25 2011-04-06 Asociación Centro de Investigación Cooperativa en Biomateriales - CIC biomaGUNE Glyconanoparticules magnétiques à revêtement en or fonctionnalisées pour une utilisation en tant qu'agents de diagnostic et de traitement
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
CA3042067C (fr) 2009-12-15 2022-10-18 Incept, Llc Implants et marqueurs de reference biodegradables
EP2537530A4 (fr) 2010-02-17 2015-12-16 Nat Univ Corp Univ Kobe Agent de radiothérapie
ES2675212T3 (es) 2010-03-26 2018-07-09 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
US8592511B2 (en) 2010-04-23 2013-11-26 Pixelligent Technologies, Llc Synthesis, capping and dispersion of nanocrystals
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
WO2012009406A2 (fr) 2010-07-13 2012-01-19 University Of Utah Research Foundation Particules d'or et leurs procédés de fabrication et d'utilisation dans le traitement du cancer
US9095558B2 (en) 2010-10-08 2015-08-04 Board Of Regents, The University Of Texas System Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
WO2012051220A1 (fr) 2010-10-11 2012-04-19 Wichita State University Système de délivrance de médicaments de nanoparticules magnétiques composites
EP2670394B1 (fr) 2011-01-31 2018-11-21 Nanobiotix Systèmes d'administration de nanoparticules, leur préparation et leurs utilisations
WO2012104277A2 (fr) 2011-01-31 2012-08-09 Nanobiotix Procédé de surveillance de la libération par des liposomes d'un produit d'intérêt au moyen de nanoparticules superparamagnétiques
KR102101806B1 (ko) * 2011-05-19 2020-04-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-인간-her3 항체 및 이의 용도
WO2013059295A2 (fr) 2011-10-17 2013-04-25 Trustees Of Boston University Dépôts polymères pour la localisation d'un agent à des sites biologiques
EP2782603A1 (fr) 2011-11-25 2014-10-01 Danmarks Tekniske Universitet Formulation de nanoparticules solides dans un système gélifiant
EA029635B1 (ru) 2011-12-16 2018-04-30 Нанобиотикс Применение наночастицы, включающей металлический материал, покрытый материалом оксида гафния, в онкологии и композиция, ее содержащая
WO2013142135A1 (fr) 2012-03-20 2013-09-26 Albert Einstein College Of Medicine Of Yeshiva University Procédé d'amélioration de l'efficacité de transfusions sanguines
US20150209397A1 (en) 2012-09-07 2015-07-30 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US20140213765A1 (en) 2013-01-25 2014-07-31 I-Liang Lee Albumin tissue scaffold
AU2014209899B2 (en) 2013-01-25 2018-05-24 Nanobiotix Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
US20140219926A1 (en) 2013-02-01 2014-08-07 The Trustees Of Dartmouth College Biodegradable Iron Oxide Nanoparticle Gel for Tumor Bed Therapy
CN105407878A (zh) 2013-05-30 2016-03-16 纳米生物技术公司 药物组合物、制备及其用途
MA38710A1 (fr) 2013-06-20 2017-12-29 Nanobiotix Compositions et procédés destinés a être utilisés en oncologie
WO2014202723A1 (fr) 2013-06-20 2014-12-24 Nanobiotix Compositions et procédés pour une utilisation en diagnostic médical
EP2886128A1 (fr) 2013-12-20 2015-06-24 Nanobiotix Compositions pharmaceutiques comportant des nanoparticules, leur préparation et leur utilisation
JP6835733B2 (ja) 2014-11-25 2021-02-24 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 医薬組成物、その調製法及び使用
EP3229776B1 (fr) 2014-11-25 2023-06-28 Curadigm Sas Composition pharmaceutique combinant au moins deux nanoparticules distinctes et un composé pharmaceutique, leur préparation et leurs utilisations
PT3229843T (pt) 2014-11-25 2020-03-06 Curadigm Sas Composição farmacêutica, a sua preparação e as suas utilizações
AU2015352688A1 (en) 2014-11-25 2017-07-13 Nanobiotix Pharmaceutical composition, preparation and uses thereof
AR102782A1 (es) 2014-11-25 2017-03-22 Nanobiotix Composición farmacéutica, su preparación y sus usos

Also Published As

Publication number Publication date
BR112017025553A2 (pt) 2018-08-07
KR20180012823A (ko) 2018-02-06
AU2016269146A1 (en) 2018-01-18
AU2021202582B2 (en) 2022-12-15
UA124572C2 (uk) 2021-10-13
US20180147237A1 (en) 2018-05-31
AU2021202582A1 (en) 2021-05-27
US11096962B2 (en) 2021-08-24
AR104806A1 (es) 2017-08-16
CA2987331A1 (fr) 2016-12-01
MX2017015424A (es) 2018-03-01
TW201705977A (zh) 2017-02-16
EP3302419A1 (fr) 2018-04-11
IL255853A (en) 2018-01-31
JP2023082080A (ja) 2023-06-13
JP2018516256A (ja) 2018-06-21
AU2016269146B2 (en) 2021-01-28
HK1246160A1 (zh) 2018-09-07
CN107708668A (zh) 2018-02-16
EA201792560A1 (ru) 2018-06-29
US20210353670A1 (en) 2021-11-18
CN118286421A (zh) 2024-07-05
WO2016189125A1 (fr) 2016-12-01
IL255853B (en) 2020-08-31
MX2023007706A (es) 2023-07-10
NZ738527A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
MA46766A (fr) Vaccin antigrippal
DK3328880T3 (da) Terapeutiske midler
DK3250263T3 (da) Medikamenttilførselsanordning
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
BR112017009342A2 (pt) formulações e tratamentos para cuidado com a pele
DK3474804T4 (da) Medicinsk forbinding
DK3519018T3 (da) Medikamentadministrationsanordning
DK3099356T3 (da) Medikamentadministrationsanordning
MA42303A (fr) Formulations pharmaceutiques
DK3258938T3 (da) Phenothiazinanaloger som mitokondrie terapeutiske midler
MA43100A (fr) Nanoparticules à utiliser en tant que vaccin thérapeutique
DK3400045T3 (da) Medikamentadministrationsanordning
DK3622986T3 (da) Medikamenttilførselsanordning
DK3316929T3 (da) Medikamenttilførselsanordning
DK3285830T3 (da) Medikamenttilførselsanordning
DK3496783T3 (da) Medikamentadministrationsanordning
DK2992967T3 (da) Medikamentdispenser
DK3349825T3 (da) Lægemiddeladministrationsanordning
DK3099357T3 (da) Medikamentadministrationsanordning
BR112016019480A2 (pt) Cateter seguro
DK3484545T3 (da) Medicinafgivelsesanordning
DK3349827T3 (da) Lægemiddeladministrationsanordning
BR112017000539A2 (pt) agente terapêutico para distúrbio ceratoconjuntivo
DK3359102T3 (da) Medicinsk plaster
UA28863S (uk) Маска медична захисна